secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2025-01-30T23:59:59+00:00
Accession:  0001193125-25-016381
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus appoints Dr. Phuong Khanh Morrow to board, effective Feb 1, 2025
-------------------------------------------------------------------------

- Dr. Phuong Khanh Morrow appointed independent director effective Feb 1, 2025; board expands to 11.
- Morrow is Head of Oncology TAU at Takeda, former CMO at CRISPR Therapeutics, and VP at Amgen.
- Will receive $60k annual cash retainer, $7.5k STC fee, initial $100k equity grant (50% RSU, 50% options), and $400k annual equity.
- Appointed to Science and Technology Committee; board now has 11 directors, 9 independent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312525016381/0001193125-25-016381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312525016381/d838877d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-016381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer